Related Experiment Video
Updated: Jan 27, 2026
Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial
Published on: August 19, 2025
C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial
Piero Ruggenenti1, Erica Daina2, Alessia Gennarini3
1Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy; Unit of Nephrology and Dialysis, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.
Rationale & Objective:
Primary membranoproliferative glomerulonephritis (MPGN) is a rare glomerulopathy characterized by complement dysregulation. MPGN progresses rapidly to kidney failure when it is associated with nephrotic syndrome. We assessed the effects of C5 convertase blockade in patients with MPGN and terminal complement activation.
Study Design:
Prospective off-on-off-on open-label clinical trial.
Setting & Participants:
Consenting patients with immune complex-mediated MPGN (n=6) or C3 glomerulonephritis (n=4) with sC5b-9 (serum complement membrane attack complex) plasma levels>1,000ng/mL and 24-hour proteinuria with protein excretion>3.5g identified from the Italian Registry of MPGN and followed up at the Istituto di Ricerche Farmacologiche Mario Negri IRCCS (Bergamo, Italy) between March 4, 2014, and January 7, 2015.
Intervention:
Anti-C5 monoclonal antibody eculizumab administered during 2 sequential 48-week treatment periods separated by one 12-week washout period.
Outcomes:
Primary outcome was change in 24-hour proteinuria (median of 3 consecutive measurements) at 24 and 48 weeks.
Results:
Median proteinuria decreased from protein excretion of 6.03 (interquartile range [IQR], 4.8-12.4) g/d at baseline to 3.74 (IQR, 3.2-4.4) g/d at 24 weeks (P=0.01) and to 5.06 (IQR, 3.1-5.8) g/d (P=0.006) at 48 weeks of treatment, recovered toward baseline during the washout period, and did not significantly decrease thereafter. Hypoalbuminemia, dyslipidemia, and glomerular sieving function improved during the first treatment period. 3 patients achieved partial remission of nephrotic syndrome and all had undetectable C3 nephritic factors before treatment. Mean measured glomerular filtration rate was 69.7±35.2 versus 87.4±55.1 and 75.8±42.7 versus 76.6±44.1mL/min/1.73m2 at the start versus the end of the first and second treatment periods, respectively, among all 10 study participants. Unlike C3, sC5b-9 plasma levels normalized during both treatment periods and recovered toward baseline during the washout in all patients.
Limitations:
Single-arm design, small sample size.
Conclusions:
Eculizumab blunted terminal complement activation in all patients with immune complex-mediated MPGN or C3 glomerulonephritis and nephrotic syndrome, but persistently reduced proteinuria in just a subgroup.
Trial Registration:
Registered in the EU Clinical Trials Register with study no. 2013-003826-10.
Insights
Eculizumab treatment for membranoproliferative glomerulonephritis (MPGN) reduced proteinuria and terminal complement activation in patients with nephrotic syndrome. However, sustained proteinuria reduction was observed only in a subgroup, highlighting the need for further research.
Area of Science:
- Nephrology
- Immunology
- Complement System
Background:
- Primary membranoproliferative glomerulonephritis (MPGN) is a rare kidney disease characterized by complement dysregulation.
- MPGN can rapidly lead to kidney failure, particularly when associated with nephrotic syndrome.
- Terminal complement activation is implicated in MPGN pathogenesis.
Purpose of the Study:
- To assess the efficacy of C5 convertase blockade using eculizumab in patients with MPGN and active terminal complement pathway.
- To evaluate the impact of eculizumab on proteinuria and markers of complement activation in this patient cohort.
Main Methods:
- A prospective, open-label, off-on-off-on clinical trial was conducted.
- Ten patients with immune complex-mediated MPGN or C3 glomerulonephritis and significant proteinuria were enrolled.
- Eculizumab was administered in two 48-week treatment periods separated by a 12-week washout.
Main Results:
- Eculizumab significantly reduced median proteinuria from baseline (6.03 g/d) to 3.74 g/d at 24 weeks (P=0.01) and 5.06 g/d at 48 weeks (P=0.006).
- Proteinuria levels returned toward baseline during washout periods.
- Serum levels of sC5b-9 (membrane attack complex) normalized during treatment and increased during washout.
- Improvements were noted in hypoalbuminemia, dyslipidemia, and glomerular filtration rate.
Conclusions:
- Eculizumab effectively blunted terminal complement activation in patients with MPGN and nephrotic syndrome.
- While proteinuria was reduced, persistent reduction was only achieved in a subgroup of patients.
- The study suggests a potential role for C5 inhibition in managing specific MPGN cases, but further investigation is warranted.
Related Concept Videos
01:16Clinical Trials
There are four phases in a clinical trial. A phase one...
01:11Clinical Trials: Overview
01:12Statistical Software for Data Analysis and Clinical Trials
01:29Neuromuscular Junction And Blockade
01:31Muscles that Move the Arm
The pectoralis major has two origins. Its clavicular head originates on the medial half of the clavicle. In contrast, the sternocostal head originates on the costal cartilages of ribs 1-6, the sternum, and the aponeurosis of the external oblique of the...
01:12Trial and Error and Algorithm